News
-
-
-
PRESS RELEASE
Carvolix announces positive 3-years clinical results for Kalios™ , the only adjustable mitral ring. 100% of patients met primary endpoint for mitral regurgitation.
Carvolix announces positive 3-year clinical results for Kalios™, the adjustable mitral ring, with 100% of patients meeting primary endpoint for mitral regurgitation. Company plans FDA submission in 2027 -
-
-
-
PRESS RELEASE
Carvolix Announces Positive Results of the Postmarketing Clinical Program Evaluating the TAVIPILOT AI Software.
Carvolix announces successful completion of postmarketing clinical program for TAVIPILOT AI software, ensuring accurate heart valve positioning during TAVI procedures with 100% procedural success -
-
-